GMT Capital Corp Raises Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

GMT Capital Corp raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 140.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 508,800 shares of the specialty pharmaceutical company's stock after purchasing an additional 296,800 shares during the period. Jazz Pharmaceuticals accounts for approximately 3.1% of GMT Capital Corp's investment portfolio, making the stock its 14th largest holding. GMT Capital Corp owned about 0.84% of Jazz Pharmaceuticals worth $62,659,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Centre Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $464,000. Franklin Resources Inc. increased its position in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after purchasing an additional 48,708 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 13.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock valued at $4,420,000 after purchasing an additional 4,332 shares during the last quarter. Finally, BTC Capital Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 9.4% in the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after purchasing an additional 4,271 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $103.38 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The business has a 50-day moving average price of $126.23 and a 200 day moving average price of $122.31. The firm has a market cap of $6.28 billion, a PE ratio of 14.56, a P/E/G ratio of 1.04 and a beta of 0.42.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares of the company's stock, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Robert Iannone sold 7,080 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now owns 82,024 shares of the company's stock, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,023,305 in the last quarter. Corporate insiders own 4.20% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on JAZZ. Piper Sandler reaffirmed an "overweight" rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley reaffirmed an "overweight" rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. HC Wainwright boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Truist Financial raised their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, Needham & Company LLC reissued a "buy" rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.